Keystone Investors PTE Ltd. Has $27.78 Million Holdings in IQVIA Holdings Inc. $IQV

Keystone Investors PTE Ltd. grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 55.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 146,228 shares of the medical research company’s stock after purchasing an additional 51,958 shares during the period. IQVIA comprises 3.2% of Keystone Investors PTE Ltd.’s portfolio, making the stock its 11th largest holding. Keystone Investors PTE Ltd. owned about 0.09% of IQVIA worth $27,775,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in IQV. Eubel Brady & Suttman Asset Management Inc. acquired a new stake in shares of IQVIA in the third quarter worth $14,278,000. OPTIMAS CAPITAL Ltd acquired a new position in IQVIA in the 3rd quarter valued at $4,008,000. Eagle Rock Investment Company LLC raised its holdings in IQVIA by 33.6% in the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after acquiring an additional 11,657 shares during the period. Amundi lifted its position in IQVIA by 46.3% during the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after acquiring an additional 405,250 shares during the last quarter. Finally, EDENTREE ASSET MANAGEMENT Ltd acquired a new stake in shares of IQVIA in the third quarter valued at about $7,368,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on IQV. Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Evercore reaffirmed an “outperform” rating and set a $225.00 target price on shares of IQVIA in a research report on Thursday, February 5th. Truist Financial reduced their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Finally, Barclays dropped their price objective on shares of IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $231.80.

IQVIA Price Performance

NYSE:IQV opened at $179.09 on Friday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The company has a 50-day moving average of $212.19 and a 200-day moving average of $207.85. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The company has a market capitalization of $30.39 billion, a price-to-earnings ratio of 22.79, a PEG ratio of 1.64 and a beta of 1.37.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the company posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.